NAYA Biosciences Share Holder Equity 2010-2024 | NAYA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

NAYA Biosciences share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

NAYA Biosciences share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$228.9B
Amgen (AMGN)	$158.1B
Gilead Sciences (GILD)	$134.2B
Vertex Pharmaceuticals (VRTX)	$121.1B
Bristol Myers Squibb (BMY)	$111.6B
CSL (CSLLY)	$80.7B
GSK (GSK)	$75.7B
Regeneron Pharmaceuticals (REGN)	$75B
Argenex SE (ARGX)	$38.9B
Alnylam Pharmaceuticals (ALNY)	$32.4B
BioNTech SE (BNTX)	$28.7B
BeiGene (ONC)	$23.2B
Biogen (BIIB)	$20B
Illumina (ILMN)	$16.3B
Insmed (INSM)	$15B
Genmab (GMAB)	$14.5B
Genmab (GNMSF)	$14.4B
Moderna (MRNA)	$13.8B
Intra-Cellular Therapies (ITCI)	$13.7B
Incyte (INCY)	$13.6B
BioMarin Pharmaceutical (BMRN)	$12.5B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Bio-Techne Corp (TECH)	$10.4B
Vaxcyte (PCVX)	$10.4B
Sarepta Therapeutics (SRPT)	$10.2B
Exelixis (EXEL)	$9.8B
Ascendis Pharma (ASND)	$9.4B
Exact Sciences (EXAS)	$9.3B
Bio-Rad Laboratories (BIO.B)	$8.7B
QIAGEN (QGEN)	$8.7B